
Crossover Study of an Oral Treatment for Sickle Cell DiseaseAward last edited on: 5/15/2017
Sponsored Program
SBIRAwarding Agency
NIH : NHLBITotal Award Amount
$224,950Award Phase
1Solicitation Topic Code
-----Principal Investigator
Robert SwiftCompany Information
Phase I
Contract Number: ----------Start Date: ---- Completed: ----
Phase I year
2017Phase I Amount
$224,950Public Health Relevance Statement:
Project Narrative About 100,000 Americans have Sickle Cell Disease. Those affected often have high medical costs, a poor quality of life, and early death. Treatment options are few. There is a substantial unmet medical need for new safe and effective disease modifying drugs, like the one in this grant, to treat this disease.
Project Terms:
Acute; Admission activity; Adult; Adverse event; Affect; Africa South of the Sahara; Age; American; Antineoplastic Agents; base; Bilirubin; Biological Markers; Birth; Bone Pain; Botanicals; capsule; Cessation of life; Child; Chronic; chronic pain; Clinical; clinically relevant; common symptom; cost; Cross-Over Studies; Crossover Design; cytokine; Data; design; Developing Countries; Disease; Dose; Double-Blind Method; Electrocardiogram; Erythrocytes; Evaluable Disease; Exposure to; Fatigue; FDA approved; Goals; Grant; Hematocrit procedure; Hematological Disease; Hemolysis; Hospitalization; hydroxyurea; In Vitro; in vivo; India; Inflammation; Inflammatory; inflammatory marker; Inherited; Laboratories; Measurement; Measures; Medical; mortality; National Heart, Lung, and Blood Institute; Numeric Rating Scale; Opiates; Oral; Organ; Pain; Patients; Pharmaceutical Preparations; Phase; phase 2 study; phase 3 study; Physical activity; Placebo Control; Placebos; Population; prevent; Primary Health Care; Quality of life; Questionnaires; Randomized; Reporting; Research; Reticulocytes; Safety; Sample Size; Schedule; Serious Adverse Event; Sickle Cell; Sickle Cell Anemia; sickling; Side; Sleep; Sleep disturbances; stroke; success; Symptoms; Testing; Thalassemia; Traditional Medicine; treatment duration; United States; Venous; Walking; Whole Blood
Phase II
Contract Number: ----------Start Date: ---- Completed: ----